Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study

H. P. Hartung*, R. Mallick, V. Bril, R. A. Lewis, G. Sobue, J. P. Lawo, O. Mielke, B. L. Durn, D. R. Cornblath, I. S. J. Merkies, I. N. van Schaik, PATH Study Group

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)196-203
Number of pages8
JournalEuropean Journal of Neurology
Volume27
Issue number1
Early online date23 Sep 2019
DOIs
Publication statusPublished - Jan 2020

Keywords

  • chronic inflammatory demyelinating polyneuropathy
  • EuroQoL 5-Dimension
  • PATH
  • quality of life
  • subcutaneous immunoglobulin
  • Treatment Satisfaction Questionnaire for Medicine
  • Work Productivity and Activity Impairment Questionnaire for General Health
  • QUALITY-OF-LIFE
  • NEUROPATHIES

Cite this